News / Taiwan / economic_daily
PharmaEssentia Revenue Surges 83% in First Nine Months
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-10-05
6446
PharmaEssentia's year-to-date revenue reached NT$19.73 billion, driven by strong sales of its rare blood cancer drug Ropeg in the U.S. and Japan.
What Happened
Revenue Growth: PharmaEssentia reported a record-breaking September revenue of NT$2.64 billion, a nearly 100% year-over-year increase. Total revenue for the first nine months of the year reached NT$19.73 billion, representing an 83.5% growth compared to the same period last year.
Market Momentum: The company's core drug, Ropeg, has seen strong demand in the U.S. and Japan following its approval for Essential Thrombocythemia (ET). Strategic marketing initiatives have successfully expanded patient coverage, significantly contributing to the company's financial performance.
Global Expansion: PharmaEssentia is actively expanding its global footprint, with Ropeg's ET indication approved in Taiwan, Japan, and the U.S. Regulatory reviews are underway in China and South Korea, and the company is preparing to file for drug approval in Australia for both PV and ET indications.
Industry Recognition: The company's achievements have been lauded by high-ranking officials, who highlighted PharmaEssentia as a model for Taiwan's biotech industry. The firm continues to solidify its position as a leader in MPN treatment through ongoing clinical trials and international market penetration.